Skip to main content
H

HEXIMA LIMITED. — Investor Relations & Filings

Ticker · HXL ISIN · AU0000111932 ASX Professional, scientific and technical activities
Filings indexed 244 across all filing types
Latest filing 2021-08-23 Regulatory Filings
Country AU Australia
Listing ASX HXL

About HEXIMA LIMITED.

https://hexima.com.au/

Hexima Limited focuses on the research and development of plant-derived proteins for human therapeutic applications. The company's primary development candidate is pezadeftide (HXM163), a proprietary plant defensin formulated as a topical treatment for onychomycosis, a fungal nail infection. Pezadeftide is engineered to penetrate the nail plate and target underlying fungal pathogens. The company's technology platform utilizes the natural defense mechanisms of plants to develop novel antimicrobial and antifungal treatments. Originally focused on agricultural biotechnology, the company transitioned to human health to address unmet needs in dermatology. Its activities involve the clinical evaluation of protein-based therapies designed to offer improved efficacy and safety profiles compared to existing antifungal treatments.

Recent filings

Filing Released Lang Actions
China Patent for Pezadeftide Granted 3 pages 221.9KB
Regulatory Filings
2021-08-23 English
Design Patent for Pezadeftide Commercial Packaging 3 pages 207.3KB
Regulatory Filings
2021-08-18 English
APMA presentation and investor webinar 24 pages 1.1MB
Regulatory Filings
2021-07-28 English
Quarterly Activities Report and Appendix 4C 12 pages 4.5MB
Regulatory Filings
2021-07-27 English
Completion of enrolment in Phase IIb Clinical Trial 3 pages 206.5KB
Regulatory Filings
2021-07-25 English
Presenting Clinical Data at APMA and Investor Webinar 3 pages 189.7KB
Regulatory Filings
2021-07-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.